Death of Genomics Maverick J. Craig Venter at 79

Venter’s passing closes a chapter that began with the 1995 sequencing of Haemophilus influenzae, an inflection point as pivotal as Alexander Fleming’s 1928 penicillin discovery in turning biology into a data-driven enterprise. His whole-genome shotgun gamble echoed the 1879 Edison–Westinghouse race over electric light: private speed challenging a slower, publicly funded effort, ultimately forcing costs down and opening the field. Over three decades, the cost of sequencing plunged from about $100 million per human genome in 2001 to roughly $200 today, part of a larger trend—automation and computation redefining life sciences much as the assembly line reshaped manufacturing in the 20th century. Whether future bioengineering giants treat DNA code as open knowledge or proprietary software will shape medicine, food, and climate technology for the next century; Venter’s career personified that unresolved tension. His death will not slow the Moore’s-law-like curve of genomics, but it bookends the era when charismatic individuals could dominate headlines before sequencing became cheap, routine infrastructure—much like aviation’s shift from the Wright brothers to commercial airlines within a generation.